| langue originale | Anglais |
|---|---|
| Pages (de - à) | 970-972 |
| Nombre de pages | 3 |
| journal | Journal of Hepatology |
| Volume | 73 |
| Numéro de publication | 4 |
| Les DOIs | |
| état | Publié - 1 oct. 2020 |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: Journal of Hepatology, Vol 73, Numéro 4, 01.10.2020, p. 970-972.
Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs
TY - JOUR
T1 - Extending the mode of action of triethylenetetramine (trientine)
T2 - Autophagy besides copper chelation
AU - Pietrocola, Federico
AU - Castoldi, Francesca
AU - Zischka, Hans
AU - Kroemer, Guido
N1 - Funding Information: GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; AMMICa US23/CNRS UMS3655; Association pour la recherche sur lecancer (ARC); Association “Le Cancer du Sein, Parlons-en!”; Cancéropôle Ile-de-France; Chanceleriedes universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation byElior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Pro-ject Oncobiome; FondationCarrefour; High-end Foreign Expert Program in China (GDW20171100085), Institut National duCancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabExImmuno Oncology (ANR-18-IDEX-0001); the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM). F.P. is supported by a Karolinska Institute Starting Grant ; Starting Grant from the Swedish Research Council ( 2019_02050_3 ). HZ is supported by the Deutsche Forschungsgemeinschaft (DFG) grant ZI1386/2-1 . Funding Information: GK is supported by the Ligue contre le Cancer (?quipe labellis?e); Agence National de la Recherche (ANR) ? Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; AMMICa US23/CNRS UMS3655; Association pour la recherche sur lecancer (ARC); Association ?Le Cancer du Sein, Parlons-en!?; Canc?rop?le Ile-de-France; Chanceleriedes universit?s de Paris (Legs Poix), Fondation pour la Recherche M?dicale (FRM); a donation byElior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Pro-ject Oncobiome; FondationCarrefour; High-end Foreign Expert Program in China (GDW20171100085), Institut National duCancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabExImmuno Oncology (ANR-18-IDEX-0001); the RHU Torino Lumi?re; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM). F.P. is supported by a Karolinska Institute Starting Grant; Starting Grant from the Swedish Research Council (2019_02050_3). HZ is supported by the Deutsche Forschungsgemeinschaft (DFG) grant ZI1386/2-1.
PY - 2020/10/1
Y1 - 2020/10/1
UR - http://www.scopus.com/inward/record.url?scp=85088968951&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2020.05.046
DO - 10.1016/j.jhep.2020.05.046
M3 - Letter
C2 - 32684364
AN - SCOPUS:85088968951
SN - 0168-8278
VL - 73
SP - 970
EP - 972
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 4
ER -